These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Buspirone in the treatment of tardive dyskinesia. Moss LE; Neppe VM; Drevets WC J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622 [TBL] [Abstract][Full Text] [Related]
5. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502 [TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342 [TBL] [Abstract][Full Text] [Related]
9. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Bai YM; Yu SC; Lin CC J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949 [TBL] [Abstract][Full Text] [Related]
10. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. Caroff SN; Walker P; Campbell C; Lorry A; Petro C; Lynch K; Gallop R J Clin Psychiatry; 2007 Mar; 68(3):410-5. PubMed ID: 17388711 [TBL] [Abstract][Full Text] [Related]
11. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Stryjer R; Strous R; Bar F; Shaked G; Shiloh R; Rozencwaig S; Grupper D; Buchman N; Kotler M; Rabey JM; Weizman A Hum Psychopharmacol; 2004 Jul; 19(5):343-6. PubMed ID: 15252826 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340 [TBL] [Abstract][Full Text] [Related]
13. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Kinon BJ; Jeste DV; Kollack-Walker S; Stauffer V; Liu-Seifert H Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):985-96. PubMed ID: 15380859 [TBL] [Abstract][Full Text] [Related]
14. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Risch SC; Horner MD; McGurk SR; Palecko S; Markowitz JS; Nahas Z; DeVane CL Schizophr Res; 2007 Jul; 93(1-3):131-5. PubMed ID: 17391930 [TBL] [Abstract][Full Text] [Related]
15. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. Chung YC; Lee CR; Park TW; Yang KH; Kim KW World J Biol Psychiatry; 2009; 10(2):156-62. PubMed ID: 19514097 [TBL] [Abstract][Full Text] [Related]
16. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341 [TBL] [Abstract][Full Text] [Related]